Status epilepticus of inflammatory etiology

Neurology

Volumn 85, Issue 5, 2015, Pages 464-470

  Spatola, Marianna ^a   Novy, Jan ^a   Du Pasquier, Renaud ^a   Dalmau, Josep ^b,c   Rossetti, Andrea O ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; AZATHIOPRINE; BENZODIAZEPINE; CORTICOSTEROID; DEXAMETHASONE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB;

ADULT; AGED; ANTICONVULSANT THERAPY; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE REGISTRY; EPILEPTIC STATE; FEMALE; FUNCTIONAL STATUS; HUMAN; INCIDENCE; INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBIDITY; MORTALITY; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR; VERY ELDERLY; YOUNG ADULT; COMPLICATION; REGISTER; STATUS EPILEPTICUS;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; RETROSPECTIVE STUDIES; STATUS EPILEPTICUS; YOUNG ADULT;

EID: 84938635303     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001717     Document Type: Article

References (48)

1. Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. Epilepsia 1999; 40:120-122.
2. DeLorenzo RJ, Hauser WA, Towne AR, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 1996;46:1029-1035.
3. Hesdorffer DC, Logroscino G, Cascino G, Annegers JF, Hauser WA. Incidence of status epilepticus in Rochester, Minnesota, 1965-1984. Neurology 1998;50:735-741.
4. Govoni V, Fallica E, Monetti VC, et al. Incidence of status epilepticus in southern Europe: a population study in the health district of Ferrara, Italy. Eur Neurol 2008;59:120-126.
5. Coeytaux A, Jallon P, Galobardes B, Morabia A. Incidence of status epilepticus in French-speaking Switzerland: (EPISTAR). Neurology 2000;55:693-697.
6. Knake S, Rosenow F, Vescovi M, et al. Incidence of status epilepticus in adults in Germany: a prospective, population-based study. Epilepsia 2001;42:714-718.
7. Towne AR, Pellock JM, Ko D, DeLorenzo RJ. Determinants of mortality in status epilepticus. Epilepsia 1994;35: 27-34.
8. Logroscino G, Hesdorffer DC, Cascino G, Annegers JF, Hauser WA. Short-term mortality after a first episode of status epilepticus. Epilepsia 1997;38:1344-1349.
9. Rossetti AO, Alvarez V, Januel JM, Burnand B. Treatment deviating from guidelines does not influence status epilepticus prognosis. J Neurol 2013;260:421-428.
10. Guidelines for epidemiologic studies on epilepsy. Commission on Epidemiology and Prognosis, International League Against Epilepsy. Epilepsia 1993;34:592-596.
11. Davis R, Dalmau J. Autoimmunity, seizures, and status epilepticus. Epilepsia 2013;54:46-49.
12. Bien CG, Scheffer IE. Autoantibodies and epilepsy. Epilepsia 2011;52:18-22.
13. Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011;69:892-900.
14. Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: a prospective observational study. Epilepsia 2010; 51:251-256.
15. Rossetti AO, Logroscino G, Milligan TA, Michaelides C, Ruffieux C, Bromfield EB. Status Epilepticus Severity Score (STESS): a tool to orient early treatment strategy. J Neurol 2008;255:1561-1566.
16. Sutter R, Kaplan PW, Rüegg S. Independent external validation of the status epilepticus severity score. Crit Care Med 2013;41:e475-e479.
17. Sutter R, Kaplan PW. The neurophysiologic types of nonconvulsive status epilepticus: EEG patterns of different phenotypes. Epilepsia 2013;54:23-27.
18. Venkatesan A, Tunkel AR, Bloch KC, et al. Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the International Encephalitis Consortium. Clin Infect Dis 2013;57:1114-1128.
19. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDAreceptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091-1098.
20. Lancaster E, Dalmau J. Neuronal autoantigens: pathogenesis, associated disorders, and antibody testing. Nat Rev Neurol 2012;8:380-390.
21. Alvarez V, Januel JM, Burnand B, Rossetti AO. Role of comorbidities in outcome prediction after status epilepticus. Epilepsia 2012;53:e89-e92.
22. Vignatelli L, Rinaldi R, Galeotti M, de Carolis P, D'Alessandro R. Epidemiology of status epilepticus in a rural area of northern Italy: a 2-year population-based study. Eur J Neurol 2005;12:897-902.
23. Holzer FJ, Rossetti AO, Heritier-Barras AC, et al. Antibodymediated status epilepticus: a retrospective multicenter survey. Eur Neurol 2012;68:310-317.
24. Holzer FJ, Seeck M, Korff CM. Autoimmunity and inflammation in status epilepticus: from concepts to therapies. Expert Rev Neurother 2014;14:1181-1202.
25. Alvarez V, Westover MB, Drislane FW, et al. Evaluation of a clinical tool for early etiology identification in status epilepticus. Epilepsia 2014;55:2059-2068.
26. Amare A, Zenebe G, Hammack J, Davey G. Status epilepticus: clinical presentation, cause, outcome, and predictors of death in 119 Ethiopian patients. Epilepsia 2008;49: 600-607.
27. Ferracci F, Bertiato G, Moretto G. Hashimoto's encephalopathy: epidemiologic data and pathogenetic considerations. J Neurol Sci 2004;217:165-168.
28. Grayson PC, Amudala NA, McAlear CA, et al. Causal attributions about disease onset and relapse in patients with systemic vasculitis. J Rheumatol 2014;41:923-930.
29. Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 2011;77:179-189.
30. Lancaster E, Lai M, Peng X, et al. Antibodies to the GABAB receptor in limbic encephalitis with seizures: a case series and characterization of the antigen. Lancet Neurol 2010;9:67-76.
31. Höftberger R, Titulaer M, Sabater L, et al. Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology 2013;81:1500-1506.
32. Jeffery OJ, Lennon VA, Pittock SJ, Gregory JK, Britton JW, McKeon A. GABAB receptor autoantibody frequency in service serologic evaluation. Neurology 2013;81:882-887.
33. Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014;13:276-286.
34. Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009;65:424-434.
35. Höftberger R, van Sonderen A, Leypoldt F, et al. Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Neurology Epub 2015 May 15.
36. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-N-methyl-D-aspartate (NMDA) receptor encephalitis: a cohort study. Lancet Neurol 2013;12:157-165.
37. Boronat A, Gelfand JM, Gresa-Arribas N, et al. Encephalitis and antibodies to DPPX, a subunit of Kv4.2 potassium channels. Ann Neurol 2013;73:120-128.
38. Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010;9:776-785.
39. Peng X, Hughes EG, Moscato EH, et al. Cellular plasticity induced by anti-AMPA receptor encephalitis antibodies. Ann Neurol 2015;77:381-398. doi: 10.1002/ana.24293.
40. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10:63-74.
41. Moscato EH, Peng X, Jain A, et al. Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2014;76:108-119.
42. Planagumà J, Leypoldt F, Mannara F, et al. Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain 2015;138:94-109.
43. Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010;30:5866-5875.
44. Mikasova L, De Rossi P, Bouchet D, et al. Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain 2012;135:1606-1621.
45. Urtecho J, Snapp M, Sperling M, et al. Hospital mortality in primary admissions of septic patients with status epilepticus in the United States. Crit Care Med 2013;41:1853-1862.
46. Novy J, Carota A, Eggimann P, Pusztaszeri M, Rossetti AO, Du Pasquier RA. Encephalitis with herpes simplex-2 in the cerebrospinal fluid and anti-RI (ANNA-2) antibodies: an infectious or a paraneoplastic syndrome? BMJ Case Rep Epub 2009 Aug 11.
47. Grujic J, Bien CG, Claudio Pollo C, Rossetti AO. Vagus nerve stimulator treatment in adult-onset Rasmussen's encephalitis. Epilepsy Behav 2011;20:123-125.
48. Maeder-Ingvar M, Prior JO, Irani SR, Rey V, Vincent A, Rossetti AO. FDG-PET hyperactivity in basal ganglia correlating with clinical course in anti-NDMA-R antibodies encephalitis. J Neurol Neurosurg Psychiatry 2011;82: 235-236.